DrugBiological
Neihulizumab clinical trials
Also written AbGn-168H.
- studies test it
- 10
- open now
- 0
- in phase 3
- 0
- first study started
- 2008
How studies write it
Studies that test it under each name
Name
Studies by the year they started
10 studies that test it; most in 2015 (2)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2011 | 1 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 2 |
| 2016 | 1 |
| 2018 | 2 |
| 2020 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 9 · Other 1
AbGenomics B.V Taiwan Branch (5) · AltruBio Inc. (2) · Boehringer Ingelheim (2) · Sameem M. Abedin, MD (1)
Studies
Open first, then newest update. How each study uses neihulizumab is read from its arms, and is right about nine times in ten.
Testing it · 10
- Neihulizumab for Standard-Risk Acute Graft Versus Host Disease (GVHD)CompletedPhase 1Sameem M. Abedin, MDNCT04144036Written as Neihulizumab, 3 mg/kg
- Efficacy&Safety of ALTB-168 in Patients With Moderate to Severe Active,Anti-TNF Alpha and/or Anti-integrin Refractory UCTerminatedPhase 2AltruBio Inc.NCT03298022Written as ALTB-168
- Neihulizumab (ALTB-168) in Patients With Steroid-refractory Acute Graft-versus-host Disease or Treatment-refractory Acute Graft-versus-host DiseaseCompletedPhase 1AltruBio Inc.NCT03327857Written as Neihulizumab (ALTB-168)
- A Study of AbGn-168H in Patients With Steroid Refractory Acute Graft-vs-Host Disease After Donor Stem Cell TransplantTerminatedPhase 1AbGenomics B.V Taiwan BranchNCT02436460Written as AbGn-168H
- A Phase II Study Evaluating the Efficacy and Safety of AbGn-168H in Patients With Active Psoriatic ArthritisCompletedPhase 2AbGenomics B.V Taiwan BranchNCT02267642Written as AbGn-168H
- A Study Evaluating the Efficacy and Safety of Neihulizumab vs "Conventional Treatment" to Treat Sr-aGvHDWithdrawnPhase 2AbGenomics B.V Taiwan BranchNCT02694770Written as Neihulizumab Treatment
- A Study of Multiple Doses of AbGn-168H by Intravenous Infusion in Patients With Moderate to Severe Chronic Plaque PsoriasisCompletedPhase 2AbGenomics B.V Taiwan BranchNCT02223039Written as AbGn-168H
- Phase IIa Study of Multiple Doses of AbGn-168H by iv Infusion in Moderate to Severe Chronic Plaque Psoriasis PatientsCompletedPhase 2AbGenomics B.V Taiwan BranchNCT01855880Written as AbGn-168H
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of AbGn-168 in PsoriasisCompletedPhase 1Boehringer IngelheimNCT00848055Written as AbGn168 intravenous infusion
- Phase I Study of AbGn-168H in Healthy Male VolunteersCompletedPhase 1Boehringer IngelheimNCT01378364Written as AbGn-168H
Codes
What other systems call neihulizumab · ClinicalTrials.gg INT015165
- UNII (FDA) 615637S5PENEIHULIZUMABOne source FDA
- NCI Thesaurus C121711NeihulizumabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 615637S5PE | NEIHULIZUMAB | One source FDA |
| NCI Thesaurus | C121711 | Neihulizumab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.